Genmab A/S (OTCMKTS:GNMSF – Get Free Report) posted its quarterly earnings results on Thursday. The company reported $5.64 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $2.15, Zacks reports. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%.
Genmab A/S Trading Down 1.5%
Genmab A/S stock traded down $8.00 during trading hours on Thursday, reaching $538.00. The stock had a trading volume of 100 shares, compared to its average volume of 5,854. The stock has a market cap of $33.12 billion, a PE ratio of 39.08 and a beta of 0.64. Genmab A/S has a 52 week low of $232.34 and a 52 week high of $581.00. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44. The company has a fifty day simple moving average of $387.72 and a 200-day simple moving average of $309.34.
Genmab A/S Company Profile
Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.
Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity.
Read More
- Five stocks we like better than Genmab A/S
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
